Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Total Current Liabilities (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Total Current Liabilities for 4 consecutive years, with $10.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 33.84% to $10.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.1 million, a 33.84% decrease, with the full-year FY2025 number at $10.1 million, down 33.84% from a year prior.
  • Total Current Liabilities was $10.1 million for Q4 2025 at Spruce Biosciences, up from $9.4 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $24.5 million in Q4 2023 to a low of $8.1 million in Q2 2025.
  • A 4-year average of $15.1 million and a median of $13.4 million in 2022 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 156.38% in 2023, then plummeted 50.98% in 2024.
  • Spruce Biosciences' Total Current Liabilities stood at $12.4 million in 2022, then skyrocketed by 96.55% to $24.5 million in 2023, then plummeted by 37.68% to $15.2 million in 2024, then crashed by 33.84% to $10.1 million in 2025.
  • Per Business Quant, the three most recent readings for SPRB's Total Current Liabilities are $10.1 million (Q4 2025), $9.4 million (Q3 2025), and $8.1 million (Q2 2025).